The goal of this study is to asses the ability of digital PCR (ddPCR) to detect actionable mutations in adult CML patients with failure of TKI therapy. The main objective of the study is it aims to answer is to assess whether ddPCR is at least as effective as NGS in detecting actionable (2GTKI-resistant) mutations.
To accomplish this aim, samples of participants treated according to clinical practice, will be taken and analyzed for the presence of BCR::ABL1 KD mutations by ddPCR.
molecularly confirmed diagnosis of BCR::ABL1+ CML;
positivity for either e13a2 or e14a2 transcript;
age ≥18 years;
chronic phase;
blastic phase;
Previous allogeneic transplant or candidate to allogeneic transplant;
on treatment with ponatinib or asciminib, investigational TKIs or non-TKI-therapy;
switch performed or planned due to intolerance and not to resistance.